American Diversifield Holdings Corporation (ADHC) Provides Update on Dexcom/GlucoGuard App Development Through UC Irvine MADO Program

Rhea-AI Summary

American Diversified Holdings (ADHC) has provided an update on its GlucoGuard app development through the University of California, Irvine's Make A Difference Opportunity (MADO) Program. During Spring 2024, the team achieved key milestones including developing a functional front-end and back-end system, training a predictive algorithm with 95% accuracy for hypoglycemic detection, and securing Registered Developer access to Dexcom API.

For Spring 2025, GlucoGuard aims to advance development to enable mobile device functionality and upgrade to Access Dexcom API for real-time blood glucose monitoring from G6 and G7 devices. The software development through UCI MADO program runs parallel to hardware development, strengthening IP claims, supporting regulatory approval, and optimizing R&D timelines.

The GlucoGuard system, being developed with three key partners including a U.S. research university, a biomedical engineering firm, and a public CGM company, combines AI and mobile monitoring to manage nocturnal hypoglycemia through an automated glucose-administering mouthpiece.

Positive

• Achieved 95% accuracy in hypoglycemic episode prediction algorithm
• Secured Dexcom API access for CGM data integration
• Parallel software development reduces overall R&D costs
• Established partnerships with three major industry players

Negative

• Hardware development still pending capital securing
• Access to Dexcom API not yet obtained

Del Mar, California--(Newsfile Corp. - February 4, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) pleased to provide the shareholder community an update on the progress Glucoguard has made in the development of the app through our engagement with the University of California, Irvine's Make A Difference Opportunity (MADO) Program.

In the Spring 2024 semester, Glucoguard was invited to participate in the MADO program through our ongoing relationship with the UCI administration. The program connects undergraduate and graduate students with local businesses, offering them hands-on experience working on real-world projects.

During our initial engagement in the program, the team achieved several key milestones:

• Developed a functional front-end and back-end capable of running on an emulator.
• Trained a predictive algorithm for detecting hypoglycemic episodes with 95% accuracy.
• Secured Registered Developer access to the Dexcom API, enabling initial integration with continuous glucose monitoring (CGM) data.

Building on this success, Glucoguard has committed to participating in the Spring 2025 round of the program. The primary objectives for this next phase include:

• Advancing the front-end and back-end development to the point where the app can be loaded and run on a mobile device.
• Upgrading to Limited Access to the Dexcom API, allowing real-time access and analysis of blood glucose values from the Dexcom G6 and G7 Continuous Glucose Monitors.

Achieving these goals will result in a fully functional mobile app capable of integrating with CGM data-an essential component of the GlucoGuard device, which requires both hardware and software development. The ability to leverage the UCI MADO program for software development is a significant advantage, as it enables IMD to advance key technical components ahead of hardware development.

Having a working app will also play a crucial role in several strategic areas:

• Intellectual Property & Patent Prosecution- A developed app strengthens IP claims by providing tangible evidence of functionality.
• Investor & Regulatory Engagement - Developing the app will serve as a key tool in showcasing the value proposition of the GlucoGuard device to analysts by providing a tangible demonstration of its functionality and potential impact. Additionally, having a fully operational app will help regulatory agencies better understand how the device integrates with continuous glucose monitoring technology, supporting a clearer and more compelling case for approval.
• Streamlining Product Development - Completing the software component in parallel with hardware development will help optimize the R&D timeline and reduce overall development costs.

As ADHC secures the capital necessary to initiate hardware development, we look forward to sharing further updates as we progress through the next phase of the program.

COMPANY OVERVIEW

Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:

1. A leading U.S. research university.
2. A highly respected biomedical and defense engineering firm.
3. A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.

Further details on these collaborations will be disclosed soon.

Cutting-Edge Technology for Unmet Medical Needs
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.

About Artificial Intelligence and Health Care
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:

1. Improving outcomes for both patients and clinical teams.
2. Lowering healthcare costs.
3. Benefitting population health.

From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment. 

Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45 minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.

Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.

See AI in healthcare: The future of patient care and health management - Mayo Clinic Press.

About the Diabetes Market
The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption.

For more information on the $28 billion diabetes market, visit: United States Diabetes Market Report.

The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions.

For details on the CGM market, visit: Continuous Glucose Monitoring Market.

Image 1

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/239485_457ac75f743d3a7e_001full.jpg

About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.

For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com

Image 2

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/239485_457ac75f743d3a7e_002full.jpg

About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com

John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com

Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.

SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239485

FAQ

What accuracy rate did ADHC's GlucoGuard achieve in detecting hypoglycemic episodes?

ADHC's GlucoGuard achieved 95% accuracy in its predictive algorithm for detecting hypoglycemic episodes during the Spring 2024 MADO program.

When will ADHC's GlucoGuard app be ready for mobile device deployment?

ADHC aims to have the GlucoGuard app ready for mobile device deployment during the Spring 2025 phase of the UCI MADO program.

What are the key partnerships for ADHC's GlucoGuard development?

ADHC's GlucoGuard is being developed in partnership with a leading U.S. research university, a biomedical and defense engineering firm, and a top publicly traded CGM sector company.

How does ADHC's GlucoGuard system manage nocturnal hypoglycemia?

GlucoGuard uses a mouthpiece that continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected, utilizing AI algorithms.

What is ADHC's current status with Dexcom API integration?

ADHC has secured Registered Developer access to Dexcom API and plans to upgrade to Access for real-time analysis of blood glucose values from Dexcom G6 and G7 monitors.